Loading the session
Loading the session
Loading instrument
$32.33
+0.00%Delayed · Pre-marketDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 16:00 IST · A quote does not mean the product is available to trade on your account.
Opens 8:00 pm IST
Opens 8:00 pm IST
Opens 8:00 pm IST
In brief
Questions investors ask
Quotes run fifteen minutes behind.
1 month: −7.6% (SPY −1.6%, XLV +13.5%). 3 months: −5.1% (SPY −0.4%, XLV +15.5%). 1 year: +14.6% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: SMTI, SPY and XLV · as of 4 Nov 2026
The 4 Nov 2026 close of $32.33 was 5.9% below its 50-day average ($34.37) and 26.2% above its 200-day average ($25.62). It has closed above the 200-day for 92 sessions, since 26 Jun 2026. The 50-day average crossed above the 200-day on 20 Jul 2026, 76 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
The 14-session relative strength index closed at 27.5 on 4 Nov 2026, its 14th session at 30 or below. By convention a reading of 30 or below is called oversold and 70 or above overbought.
Daily closes, split-adjusted; Wilder's 14-session RSI · as of 4 Nov 2026
Closed at $32.33 on 4 Nov 2026: 9.0% below the 52-week high of $35.52 (15 Oct 2026) and 101.5% above the low of $16.05 (25 Mar 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
374.8K shares were sold short at the 15 Oct 2026 settlement, 4.1% of the 9.2M shares outstanding; covering them would take 1.8 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.
November 12, 2025
−24.71%August 13, 2025
+16.20%November 14, 2023
+19.36%